DeepCure

AI-driven Drug Discovery

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in September 2018 by Kfir Schreiber, Thrasyvoulos (Thras), and Joseph Jacobson, DeepCure operates with 11–50 employees. The company has raised $46 million across two funding rounds, with Morningside Venture Investments leading a Series A round in November 2021.

Business overview

DeepCure develops an AI platform for drug discovery, leveraging deep learning algorithms, cloud computing infrastructure, and a proprietary database of over 1 trillion chemistries. The platform, which includes its MolDB molecular database, is designed to identify drug candidates that offer improved value to patients. DeepCure serves the pharmaceutical and biotechnology industries, operating within the Health Tech & Life Sciences sector, specifically focusing on drug development and discovery.

Strategic signal

In January 2023, DeepCure partnered with Biosero to establish a fully automated, AI-powered chemistry synthesis platform. This collaboration signals a strategic move towards enhancing the efficiency and scalability of DeepCure's drug discovery process, indicating a commitment to integrating advanced automation into its AI-driven approach to accelerate the identification and development of new drug candidates.

Company Intelligence Q&A

What is DeepCure's core technology?
DeepCure utilizes an AI platform that combines deep learning algorithms, cloud computing infrastructure, and a proprietary database of over 1 trillion chemistries to search for drug candidates with high accuracy.
When did DeepCure secure its Series A funding?
In November 2021, DeepCure closed its Series A funding round, which was led by Morningside Venture Investments.
What is the purpose of DeepCure's MolDB?
DeepCure's proprietary MolDB is a large medicinal chemistry database covering over 1 trillion compounds, expandable to 1 quintillion molecules, enabling the discovery of candidates not found in traditional screening libraries.
What was a significant recent collaboration for DeepCure?
In January 2023, DeepCure collaborated with Biosero to establish a fully automated, AI-powered chemistry synthesis platform, aiming to streamline and accelerate drug discovery.
Who are the founders of DeepCure?
DeepCure was founded by Kfir Schreiber, Thrasyvoulos (Thras), and Joseph Jacobson in September 2018.

External links